Fig. 1
Management algorithm for nAMD patients undergoing anti-VEGF T&E regimens. 1Stable vision is defined as BCVA gain or BCVA loss < 5 ETDRS letters (or 1 line of Snellen chart). 2VA and OCT assessment should be conducted at visit of the third injection. 3Absence of macular hemorrhage and neovascularization is required. 4Non-increased fluid after 3 more consecutive monthly injections following initial treatment could be considered as persistent fluid, and the injection interval could be extended if VA is stable. 5Active disease is defined as any increased fluid with BCVA loss ≥5 ETDRS letters (or 1 line of Snellen chart), new macular hemorrhage, or new neovascularization. 6For patients with either increased fluid or BCVA loss ≥5 ETDRS letters alone, the treatment interval could be maintained or shortened. 7Patients who have met the exit criteria with serous PED should be monitored frequently (e.g. monthly or bi-monthly). BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; nAMD, neovascular age-related macular degeneration; OCT, optical coherence tomography; PED, pigment epithelial detachment; T&E, treat-and-extend; VA: visual acuity; VEGF, vascular endothelial growth factor